CSIMarket
 
Landos Biopharma Inc   (LABP)
Other Ticker:  
 
 
Price: $6.6400 $0.16 2.469%
Day's High: $6.64 Week Perf: 6.24 %
Day's Low: $ 6.30 30 Day Perf: 25.52 %
Volume (M): 3 52 Wk High: $ 6.73
Volume (M$): $ 19 52 Wk Avg: $3.49
Open: $6.49 52 Wk Low: $0.23



 Market Capitalization (Millions $) 41
 Shares Outstanding (Millions) 6
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) 2
 Cash Flow (TTM) (Millions $) 36
 Capital Exp. (TTM) (Millions $) 0

Landos Biopharma Inc
Landos Biopharma Inc is a biotechnology company that focuses on developing and commercializing novel therapeutics for autoimmune diseases. The company specializes in utilizing its proprietary platform, called LANCE, to discover and develop oral peptide-based therapies that target specific disease pathways. Landos Biopharma aims to improve the quality of life for patients suffering from autoimmune diseases by providing effective and convenient treatment options.


   Company Address: 1800 Kraft Drive Blacksburg 24060 VA
   Company Phone Number: 218-2232   Stock Exchange / Ticker: NASDAQ LABP
   LABP is expected to report next financial results on March 22, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Landos Biopharma Inc

Landos Biopharma Inc Demonstrates Encouraging Progress with Operating Loss Reduction of $-6.479 Million in Q1 2023

The first quarter of the reporting cycle for 2023 has seen a number of corporations in the Major Pharmaceutical Preparations sector declare their results, with notable changes in operating losses amongst the entities. Landos Biopharma Inc, for instance, reported an operating loss of $-6.479 million in the first quarter of 2023, which pales in comparison to the loss of $-12.403 million reported in the same period of 2021. This is a significant sign for the state of the company.
As a rising business in the sector, Landos Biopharma Inc continues to evolve its business model, with numerous stakeholders looking to the company's efficiency in running its operations. During the financial first quarter of 2023, executives successfully managed Landos Biopharma more effectively, reducing the company's deficit to $-6.034 million. This marks an improvement on the previous year, indicating that the company is moving in the right direction towards profitability.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com